Company intelligence / Profile preview

Halia Therapeutics

Lehi/Salt Lake City*, Utah, USAhaliatx.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

Halia’s lead candidate HT‑6184—a first-in-class NEK7/NLRP3 inhibitor—has completed a Phase I study demonstrating safety/tolerability in healthy volunteers. Two Phase II trials have been launched targeting chronic inflammation-driven conditions including obesity/metabolic dysfunction and LR-MDS. Preclinical data show broad anti-inflammatory effects across multiple organ systems.

Therapeutic areas: GastroenterologyMetabolic DisordersImmunologyDermatologyHematologyNeurology
Modalities: Small molecules (allosteric modulators)
Industry: Biotech

Drug pipeline

4 assets

HT-4253

3 more assets in the full pipeline.

Request access →

Partnerships

Novo Nordisk Golden Ticket/BioLabs European Award recipient for obesity/inflammation research support and mentorship from Novo Nordisk advisors.

Beyond the preview

Go deeper on Halia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halia Therapeutics.

Explore the full profile